Key Takeaways
- “Chinese herbal medicine” may mean individually dispensed decoction pieces, concentrated granules, a manufactured patent medicine, a hospital preparation or a non-drug supplement; the quality and regulatory questions differ.
- Safety has three separate dimensions: correct identity and quality, the herb’s own toxicity, and interactions with diseases or other treatments.
- Review the complete formula and complete medication list. Checking one famous ingredient or spacing doses by a few hours is not enough.
- Keep the prescription, package, manufacturer, lot, expiry and dispensing source so a suspected adverse reaction can be investigated.
- Stop and obtain medical advice for jaundice, dark urine, severe rash, breathing difficulty, unusual bleeding, persistent vomiting, confusion or rapid deterioration.
Content
Herbal medicines are pharmacologically active products. Their risk is not captured by the word “natural,” and their quality cannot be judged by smell, colour or price. A safe decision begins by identifying exactly what is being supplied, who prescribed and dispensed it, how the ingredients were sourced and processed, what else the patient takes, and what outcome will be monitored.
Identify the product category before discussing safety
Ask the prescriber or pharmacy which of the following is being supplied:
- Chinese herbal pieces (中药饮片): named materials, often processed, weighed into individual prescriptions and prepared as a decoction or powder;
- formula granules (中药配方颗粒): concentrated single-herb granules combined according to a prescription;
- Chinese patent medicine (中成药): a finished manufactured product with a fixed formulation and labelled dosage form;
- medical-institution preparation (医疗机构制剂): a preparation made under an institution-specific authorisation for that institution’s clinical need;
- food, tea or dietary/health supplement: a product whose regulatory status may not be that of a medicine, even if the marketing sounds therapeutic.
These categories are not interchangeable. A prescription copied from decoction pieces cannot be converted to concentrated granules gram for gram without product-specific knowledge. A hospital preparation may have restrictions on where it can be dispensed. A “health food” number is not a drug approval. Record the exact regulatory and dosage form rather than calling everything “herbal tablets.”
China’s Drug Administration Law requires drug distributors and medical institutions to check quality documentation, labels and batch information, maintain purchase and sale records, and use qualified pharmacy personnel for prescription review and dispensing [1]. Patients may not see the whole supply-chain file, but the dispensing institution should be able to trace what it supplied.
Separate three kinds of risk
Identity and quality failure. The wrong species, plant part, processing method or substitute may be used. Finished products may contain undeclared medicines; raw materials may carry pesticides, heavy metals, microorganisms, mycotoxins or foreign matter. NCCIH has documented these types of safety concern in Chinese herbal products [2]. WHO quality-control guidance includes methods for identity and for contaminants such as pesticide residues, toxic metals, microorganisms and aflatoxins [3].
Intrinsic toxicity. A correctly identified herb can still harm the liver, kidney, heart, nervous system or other organs at a particular dose, duration or in a vulnerable patient. Processing may reduce or alter toxicity; it is part of the prescription, not a decorative detail. “Traditional compatibility” does not eliminate dose-dependent toxicity.
Interaction. An herb may alter absorption, metabolising enzymes, transporters or excretion of another drug. It may also add to anticoagulation, sedation, immune effects, blood-pressure or glucose lowering, electrolyte changes or organ toxicity. Because a formula contains multiple ingredients, its interaction profile is not equal to that of a single herb searched online.
Product standards reduce uncertainty but do not prove clinical suitability
The 2025 edition of the Pharmacopoeia of the People’s Republic of China is a current national drug standard and includes applicable specifications and methods [4]. China also has Good Agricultural Practice requirements for standardised production of Chinese crude drugs, including cultivation or breeding, harvesting, processing at origin and supply-chain quality management [5]. These systems address quality; they do not prove that a product is effective for a particular person or compatible with their medicines.
For a dispensed product, ask:
- the exact Chinese name of every ingredient and amount per daily dose;
- plant, animal or mineral source and processed form where relevant;
- manufacturer or prepared-piece supplier;
- prescription or product approval/filing information appropriate to its category;
- lot number, expiry and storage conditions;
- whether the pharmacy can retrieve incoming inspection or supplier information for that batch;
- what testing applies to identity, potency or marker compounds, microorganisms, pesticides, heavy metals and other relevant contaminants;
- whether substitutions are allowed and how they are documented.
A certificate or “laboratory tested” badge is useful only if it identifies the product, batch, laboratory, methods, specifications and results. It does not substitute for a valid prescription or interaction review.
The prescription must be reconstructable
China’s Prescription Management Measures require prescription elements, legal measurement units, and special instructions for Chinese herbal pieces such as decocting first, adding later or wrapping [6]. Hospital standards require pharmacy review of recognised incompatibilities, pregnancy cautions and unusually high doses before dispensing [7].
Keep a copy containing the patient, date, diagnosis, prescriber, every ingredient and gram amount, processing requirement, number of doses, preparation instructions, administration schedule and duration. For prepared decoctions, record how many bags were supplied, storage temperature, shelf life and reheating instructions. For granules or manufactured medicines, retain the original container and leaflet.
Do not accept a bag labelled only “sleep formula” or an invoice without composition. If a clinician says the formula is proprietary, the patient and treating doctors still need enough ingredient information to give informed consent and manage interactions or poisoning.
Screen the person, not just the product
Extra review is warranted for:
- liver or kidney disease, abnormal laboratory results or previous drug-induced injury;
- pregnancy, attempts to conceive or breastfeeding;
- children, frail older adults or people with low body weight;
- planned surgery, dental extraction or an invasive procedure;
- bleeding disorders or anticoagulant/antiplatelet treatment;
- cancer therapy, transplant immunosuppression or immune-modifying drugs;
- antiseizure medicines, sedatives and psychiatric medicines;
- diabetes or blood-pressure treatment;
- medicines with a narrow therapeutic range;
- multiple new symptoms or an uncertain diagnosis.
NCI explains that herbs and supplements may change how cancer drugs are absorbed, distributed, metabolised or excreted [8]. The same principle matters in other high-risk regimens. Ask the prescribing specialist or a pharmacist to review the exact formula—not merely whether “TCM” is permitted.
Do not stop a prescribed drug or reduce its dose to make room for an herbal product without the prescriber. Separating doses by two or four hours may reduce some direct absorption effects, but it does not remove longer effects on enzymes, bleeding, glucose, immunity or organs.
Decide what monitoring is proportionate
Monitoring should follow the product, duration, patient vulnerability and suspected toxicity. It may include a symptom and function baseline, blood pressure or glucose, medication levels, blood count, liver or kidney tests, or no laboratory testing for a short low-risk exposure. A fixed “liver detox panel” sold to everyone is not individual monitoring.
Before starting, agree on:
- the exact symptom or function target;
- how change will be measured;
- the first review date;
- expected common effects;
- symptoms or laboratory changes that require stopping;
- who receives results and who decides whether to continue.
If several products are started together, it becomes difficult to identify benefit or harm. When clinically feasible, add one major change at a time. Avoid automatic repeat dispensing without checking whether the diagnosis, medicines, pregnancy status or organ function has changed.
Recognise an adverse reaction early
Seek urgent medical assessment for breathing difficulty, facial or throat swelling, collapse, severe blistering rash, chest pain, major bleeding, confusion, seizures or rapidly worsening illness. Stop the suspected new product and contact a clinician promptly for jaundice, dark urine, pale stools, severe or persistent abdominal pain, repeated vomiting, widespread rash, unusual bruising, very low urine output, new palpitations or marked weakness.
Bring the remaining product, package, prescription, receipt and timeline. Do not throw everything away before lot and ingredient details are recorded. China has a national adverse drug reaction reporting system; manufacturers, distributors and medical institutions have reporting and monitoring duties, and citizens are also encouraged to report [9]. A report records suspicion—it does not require proof before submission.
Surgery, cancer treatment and other time-sensitive care
Tell the surgical, anesthesia, oncology and pharmacy teams about every herbal product well before treatment. Do not rely on a universal instruction such as “stop all herbs seven days before surgery”; the correct pause depends on ingredients, bleeding, glucose, blood pressure, sedation, organ function and the procedure. The responsible medical team should set and document the stop and restart dates.
During cancer treatment, do not take products advertised as immune boosters, antioxidants, liver protectors or chemotherapy detoxifiers without regimen-specific review. A supportive claim may still conflict with the intended mechanism or toxicity monitoring of treatment. If an oncology trial is involved, disclose products to the trial team because protocol rules may apply.
Travel and handover
Keep products in original labelled containers or pharmacy bags and carry the signed prescription plus an English ingredient list. Check the rules of China, the destination and every transit country. China Customs states that reasonable personal quantities of herbs and Chinese patent medicines may be taken or mailed abroad when they are not prohibited or restricted, but specified animal, plant, toxic or protected materials are restricted [10]. The destination may also treat a product as a medicine, food, plant material or wildlife item.
Before returning home, give the clinician or pharmacist the complete formulation, dose, start and stop dates, purpose, response, adverse effects and relevant test results. If the ingredients cannot be reliably identified, continuing the product across borders is difficult to justify.
A short quality-and-safety checklist
- What legal product category and dosage form is this?
- Can every ingredient and amount be read and translated accurately?
- Who prescribed, dispensed and manufactured or supplied it?
- Which lot and expiry apply, and can the batch be traced?
- What intrinsic toxicity, contamination and substitution risks are relevant?
- Has the complete formula been checked against the complete medicine list?
- Are pregnancy, organ function, surgery and major comorbidities accounted for?
- What outcome, monitoring, review date and stopping rule are written down?
- Can an adverse event be reported with the information retained?
Medical disclaimer: This guide is general educational information, not a prescription or product-quality determination. Herbal medicines should be reviewed by qualified clinicians and pharmacists with access to the full history and product details. Severe or rapidly worsening symptoms require urgent local care.
FAQ
Are concentrated granules equivalent to the same gram amount of raw herbal pieces?
Not necessarily. Extraction ratio, concentration, excipients and manufacturer specifications matter. Use the product-specific prescription and instructions rather than converting gram for gram.
Does a Chinese Pharmacopoeia standard prove that a formula is effective?
No. A pharmacopoeial standard addresses identity, quality specifications and testing. Clinical suitability, dose, evidence and interactions still need an individual assessment.
Is taking herbs two hours apart from prescription medicines enough?
Often not. Separation may help with some direct absorption issues, but it cannot reliably prevent effects on metabolism, transporters, bleeding, glucose, immunity or organ toxicity.
What information should be kept if an adverse reaction is suspected?
Keep the prescription, complete ingredient list, package, manufacturer, lot, expiry, dispensing source, receipt, dose timeline, symptoms, other medicines and relevant test results. Seek medical care first when symptoms are serious.
Can loose herbs be taken on an international flight?
Rules vary by ingredient and country. Original labels, a prescription and an accurate ingredient list help, but medicines, plant materials and protected species may still be restricted; check all exit, transit and destination rules before travel.
Sources
- National Medical Products Administration of China — Drug Administration Law of the People’s Republic of China
- US National Center for Complementary and Integrative Health — Traditional Chinese Medicine: What You Need to Know
- World Health Organization — Quality Control Methods for Herbal Materials
- National Medical Products Administration of China — 2025 Edition of the Pharmacopoeia of the People’s Republic of China
- National Medical Products Administration of China — Good Agricultural Practice for Chinese Crude Drugs
- National Health Commission of China — Prescription Management Measures
- National Health Commission of China — Management Standards for Chinese Herbal Pieces in Hospitals
- US National Cancer Institute — Cancer Therapy Interactions With Foods and Dietary Supplements
- National Medical Products Administration of China — Provisions for Adverse Drug Reaction Reporting and Monitoring
- General Administration of Customs of China — Rules for Carrying or Mailing Chinese Herbs and Patent Medicines Abroad
Image Review
- Decision: Approved for publication and retained as hero-simple.png.
- Editorial note: The clinician and patient are visibly comparing a prescription medicine, capsule and plant ingredient on one list, while labelled containers and loose roots support the identity, interaction and quality-control theme. No cure claim or unsafe preparation is shown.